Total (N = 583) | SGLT2-I users (N = 98) | Non-SGLT-I users (N = 485) | p value | |
---|---|---|---|---|
Age, n (%) | 71 [61–79] | 65 [58–74] | 72 [62–80] | < 0.001 |
Male Sex, n (%) | 444 (76.2) | 80 (81.6) | 364 (75.1) | 0.163 |
BMI, Kg/m2 | 28.3 ± 4.9 | 28.2 ± 4.9 | 28.4 ± 5 | 0.577 |
BSA, m2 | 1.9 ± 0.2 | 1.9 ± 0.3 | 1.9 ± 0.2 | 0.145 |
Smoking, n (%) | 337 (57.8) | 62 (63.3) | 275 (56.7) | 0.230 |
Hypertension, n (%) | 485 (83.2) | 87 (88.8) | 398 (82.1) | 0.105 |
Dyslipidemia, n (%) | 460 (78.9) | 84 (85.7) | 376 (77.5) | 0.07 |
PAD, n (%) | 70 (12) | 13 (13.3) | 57 (11.8) | 0.674 |
COPD, n (%) | 78 (13.4) | 13 (13.3) | 65 (13.4) | 0.971 |
CKD, n (%) | 51 (8.7) | 8 (8.2) | 43 (8.9) | 0.822 |
Previous TIA/CVA, n (%) | 46 (7.9) | 9 (9.2) | 37 (7.6) | 0.603 |
Previous AMI, n (%) | 152 (26.1) | 29 (29.6) | 123 (25.4) | 0.384 |
Previous PCI, n (%) | 166 (28.5) | 33 (33.7) | 133 (27.4) | 0.211 |
AF, n (%) | 53 (9.1) | 9 (9.2) | 44 (9.1) | 0.972 |
Antiplatelets, n (%) | 293 (50.3) | 52 (53.1) | 241 (49.7) | 0.543 |
Anticoagulation, n (%) | 50 (8.6) | 5 (5.1) | 45 (9.3) | 0.178 |
RAAS-I, n (%) | 330 (56.6) | 64 (65.3) | 266 (54.8) | 0.07 |
Diuretics, n (%) | 170 (32) | 26 (26.5) | 144 (29.7) | 0.820 |
B-blockers, n (%) | 255 (43.7) | 47 (48) | 208 (42.9) | 0.356 |
CCB, n (%) | 156 (26.8) | 22 (22.4) | 134 (27.6) | 0.291 |
Statins, n (%) | 284 (48.7) | 54 (55.1) | 230 (47.4) | 0.165 |
Low/moderate intensity | 203 (71.5) | 35 (64.8) | 173 (75.2) | 0.120 |
High intensity | 81 (28.5) | 19 (35.2) | 57 (24.8) | |
Ezetimibe, n (%) | 70 (12) | 13 (13.3) | 57 (11.8) | 0.674 |
Metformin, n (%) | 420 (72) | 72 (73.5) | 348 (71.8) | 0.730 |
Sulfonylureas, n (%) | 157 (26.9) | 12 (12.2) | 145 (30) | 0.001 |
DPP-4 Inhibitors, n (%) | 47 (8.1) | 7 (7.1) | 40 (8.2) | 0.714 |
GLP-1 Agonist, n (%) | 14 (2.4) | 3 (3.1) | 11 (2.3) | 0.640 |